Perceptive Advisors LLC Acquires 1,629,027 Shares of Alto Neuroscience, Inc. $ANRO

Perceptive Advisors LLC boosted its holdings in Alto Neuroscience, Inc. (NYSE:ANRO) by 1,048.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,784,393 shares of the company’s stock after buying an additional 1,629,027 shares during the period. Perceptive Advisors LLC owned approximately 0.06% of Alto Neuroscience worth $31,762,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Torren Management LLC bought a new position in Alto Neuroscience in the 4th quarter worth approximately $62,000. Balyasny Asset Management L.P. acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth approximately $198,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth approximately $221,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth approximately $304,000. Finally, ExodusPoint Capital Management LP acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth approximately $334,000.

Alto Neuroscience Price Performance

Shares of ANRO stock opened at $21.87 on Thursday. The stock’s fifty day simple moving average is $22.68 and its 200 day simple moving average is $19.72. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The firm has a market cap of $767.49 million, a price-to-earnings ratio of -9.04 and a beta of 1.22. Alto Neuroscience, Inc. has a one year low of $2.15 and a one year high of $28.44.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). On average, analysts expect that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ANRO shares. Weiss Ratings raised Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. JonesTrading decreased their price objective on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Wedbush lifted their price objective on Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Finally, HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a report on Wednesday. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.25.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.